Conjugate Vaccine vs Polysaccharide Vaccine

Overview

Many nations have faced significant health challenges from meningitis caused by microorganisms such as Haemophilus influenzae type B (HIB), Streptococcus pneumoniae, and Neisseria meningitidis. The creation of vaccines brings promise for stopping these diseases. Conjugate vaccines show strong effectiveness in disease prevention. The study first explores the basic principles of conjugate and polysaccharide vaccines then compares them while also detailing their practical applications.

Concepts and Components

1. Polysaccharide Vaccines

Concept: Bacterial capsular polysaccharides (CPS) extracted and purified from bacterial surfaces are used to produce polysaccharide vaccines. The polysaccharides act as antigens which stimulate immune responses from the immune system specifically targeting bacteria.
Principle: Polysaccharide vaccines stimulate B cells to create antibodies in a T-cell independent manner. Polysaccharide vaccines trigger only B cell responses while failing to create long-term memory despite antibody production. Further immunizations do not strengthen immune responses and they produce antibody levels that fall short of initial immune responses.
Components: Capsular polysaccharides extracted and purified from bacteria form the primary components of polysaccharide vaccines. Bacterial surface polysaccharides act as antigenic components which stimulate the immune system to produce targeted antibodies.

2. Conjugate Vaccines

Concept: The production of conjugate vaccines depends on chemically bonding bacterial capsular polysaccharides with carrier proteins. Conjugation turns polysaccharide antigens into T-cell dependent substances which leads to enhanced immune reactions.
Principle: Conjugate vaccines function by connecting polysaccharide antigens to protein carriers which enables their processing by the immune system through T-cell dependent pathways. Polysaccharide antigen conjugation strengthens immune response stimulation and supplies CD4+ T cell epitopes that aid specific antibody production and lasting immune memory formation.
Components: The primary antigenic component of conjugate vaccines includes purified bacterial capsular polysaccharides which are connected to carrier proteins like diphtheria toxoid CRM197 or tetanus toxoid to activate T cell responses through polysaccharide binding.

Similarities and Differences Between Conjugate Vaccines and Polysaccharide Vaccines

Comparison Dimension	Conjugate Vaccines	Polysaccharide Vaccines
Similarities
Antigen Basis	The primary antigenic component consists of bacterial capsular polysaccharides, which are key structural elements on bacterial surfaces and stimulate immune responses.	The primary antigenic component consists of bacterial capsular polysaccharides, which are key structural elements on bacterial surfaces and stimulate immune responses.
Prevention Target	Designed to protect against serious bacterial infections such as pneumonia and meningitis.	Designed to protect against serious bacterial infections such as pneumonia and meningitis.
Immune Mechanism	Antibody production is the primary defense mechanism to eliminate pathogens.	Antibody production is the primary defense mechanism to eliminate pathogens.
Differences
Immune Mechanism	Activates T-cell-dependent immune responses by binding to protein carriers, resulting in high antibody titers and immune memory.	Activates only B-cell responses, leading to weaker immunogenicity, low antibody titers, and no long-term memory.
Target Population	Effective for diverse populations, including infants under 2 years old.	Less effective in children under 2 years old and primarily suitable for adults and older children.
Immune Memory	Generates durable immune memory, allowing for rapid immune responses upon subsequent encounters with the same pathogen.	Fails to create lasting immunity, as additional doses do not enhance protection.
Cross-Protection	Provides partial cross-protection against related serotypes.	Offers limited cross-protection, mainly targeting specific serotypes.
Production Complexity	Production is more complex due to the need to chemically link polysaccharides to protein carriers, leading to higher costs and potential stability challenges.	Production is simpler, less expensive, and more stable.
Immunogenicity	Strong immunogenicity, suitable for all age groups.	Weaker immunogenicity, particularly in infants.

Specific Application Examples

Disease	Polysaccharide Vaccine	Conjugate Vaccine	Notes
Pneumococcal	PPV23 (23-valent pneumococcal polysaccharide vaccine): Targets 23 pneumococcal serotypes. Suitable for adults over 65 and individuals aged 2–64 with specific health issues. Reduces the severity of community-acquired pneumonia (CAP) but has limited effectiveness against non-invasive pneumonia.	PCV13 (13-valent pneumococcal conjugate vaccine): Contains 13 pneumococcal serotypes linked to a protein carrier. Effective in children and protects adults from invasive pneumococcal disease. Studies show it reduces IPD in children and lowers pneumococcal infection rates in adults.	PCV13 is effective across age groups, while PPV23 is primarily for adults.
Hib	Hib Polysaccharide Vaccine: Demonstrated limited effectiveness before conjugate vaccines were introduced, as it failed to elicit adequate immune responses in infants.	Hib Conjugate Vaccine: Combines Hib polysaccharide antigen with a protein carrier to activate T-cell responses, providing protective immunity in infants. Led to a significant reduction in Hib disease cases and nearly eradicated it in vaccinated infants.	Hib conjugate vaccines significantly improved immune response and nearly eliminated Hib disease in infants.
Meningococcal	Meningococcal Polysaccharide Vaccine: Targets specific serogroups to prevent meningococcal disease but shows inadequate immunogenicity when administered to infants.	Meningococcal Conjugate Vaccine: Polysaccharide antigens are conjugated to protein carriers, enhancing immunogenicity and protection in infants, leading to more effective prevention of meningococcal diseases.	Conjugate vaccines provide better immune responses in infants compared to polysaccharide vaccines.

COPD Exacerbation Rate Across Study Groups Figure 1. Dynamics of the Chronic obstructive pulmonary disease exacerbation rate in the different study groups. (Source: Ignatova GL, et al. 2021)

Conclusion

While every vaccine type is vital for bacterial disease prevention, they function through distinct mechanisms to trigger immune responses and build immune memory alongside other special properties. Conjugate vaccines enhance infant vaccination efficacy through the combination of polysaccharide antigens and protein carriers which create more durable and robust immune protection. Conjugate vaccines create robust protection for young children and immunocompromised patients even though they cost more to produce. As vaccine technology evolves it results in increased use of conjugate vaccines which improve human health protection.

References

Kalita P, Padhi AK, Zhang KJ, Tripathi T. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2. Microb Pathog. 2020;145:104236.
Zhao J, Hu G, Huang Y, Huang Y, Wei X, Shi J. Polysaccharide conjugate vaccine: A kind of vaccine with great development potential. Chin Chem Lett. 2021;32(4):1331–1340.
Ignatova GL, Avdeev SN, Antonov VN. Comparative effectiveness of pneumococcal vaccination with PPV23 and PCV13 in COPD patients over a 5-year follow-up cohort study. Sci Rep. 2021;11:15948.

Reagent Solutions

Pathogenic Bacteria ELISA Kits

Target	Cat. No.	Product Name	Size	Species	Application	Detection Sample
S. enterica	DEIA8603	Salmonella Typhi IgM ELISA Kit	96T	Human	Quantitative	serum, plasma	Inquiry
Shiga Toxins	DEIASL162	Shiga toxins ELISA Kit	96T	Human	Qualitative	Fecal	Inquiry
S. aureus Enterotoxins	DEIA-CL032	Human Staphylococcus Aureus Enterotoxins (SE) ELISA Kit	48T, 96T	Human	Quantitative	serum, plasma, tissues Homogenate, Feces, urine, Body Fluids	Inquiry
E. coli	DEIA2348	E. Coli Verotoxin (Fecal) ELISA Kit	96T		Qualitative	stool supernatant	Inquiry
	DEIA2562	E.coli Antigen In Food ELISA Kit	96T		Quantitative	food	Inquiry
	DEIA2437	E.Coli O157 (Fecal) ELISA Kit	96T		Qualitative	feces	Inquiry
E. coli CAT	DEIA8703	CAT ELISA Kit	96T		Quantitative	eukaryotic cells	Inquiry
E. coli LPS	DEIA-LL289	LPS (Lipopolysaccharides) ELISA Kit	96T	Universal	Quantitative	Bacterial cell walls of gramnegative bacteria, tissue homogenates, other biological fluids	Inquiry
E. coli O157	DEIA-NS2402-6	E.coli O157 ELISAKit	96T	Human	Quantitative	ground beef, milk, lettuce, etc	Inquiry
E. coli Verotoxin (SLT-2b)	ABPR-ZB223	E.coli Shiga toxin II subunit B Antibody Pair Set	5 Plates, 15 Plates	E.coli	sELISA		Inquiry
E. granulosus	DEIA1777	Human Echinococcus granulosus IgG ELISA Kit	96T	Human	Semi-quantitative	Serum, plasma	Inquiry
	DEIA1095	Echinococcus IgG ELISA Kit	96T		Qualitative	serum	Inquiry
	DEIA1096	Echinococcus IgM ELISA Kit	96T		Qualitative	serum	Inquiry
E. histolytica	DEIA2309PY	Entamoeba histolytica Ag ELISA Kit	96T		Qualitative	stool	Inquiry
	DEIA1674	Human Entamoeba histolytica IgG (Amebiasis) ELISA kit	96T	Human	Qualitative	Human serum or plasma (citrate, heparin)	Inquiry
	DEIA7704	Entamoeba histolytica IgG ELISA Kit	96T	Human	Qualitative	serum, plasma	Inquiry
	DEIA2309PY-1	Entamoeba Ag ELISA Kit	96T	Human	Qualitative	Stool	Inquiry
E.coli HCP	DEIABL481	E.coli HCP ELISA kit	96T	E.coli	Quantitative	Host cells	Inquiry
	DEIA-HCP23-3	E.coli HCPs(E.coli host cell proteins) ELISA Kit	96T	N/A	Quantitative	biological products	Inquiry
	DEIA-JY2302	E.coli HCP (Alkaloid cleavage) ELISA Kit	96T		Quantitative	Biological samples	Inquiry
	DEIA-JY2303	E.coli HCP (Expression strain) ELISA	96T		Quantitative	Biological samples	Inquiry
	DEIABL481NS	E.coli HCP ELISA kit	96T	N/A	Quantitative	host cells	Inquiry
F. tularensis	DEIA-XY127	Francisella tularensis IgG ELISA Kit	96T	Human	Quantitative	serum, EDTA plasma, heparin plasma, citrate plasma	Inquiry
	DEIA-XY128	Francisella tularensis IgM ELISA Kit	96T	Human	Quantitative	serum, EDTA plasma, heparin plasma, citrate plasma	Inquiry
	DEIASL279	Human Anti-Francisella tularensis ELISA Kit	96T		Qualitative	Serum	Inquiry

Hib ELISA Kits

Target	Cat. No.	Product Name	Size	Species	Application	Detection Sample
H. influenza B	DEIA1650	Human Haemophilus Influenza B IgG ELISA Kit	96T	Human	Qualitative	serum, plasma	Inquiry
H. influenzae	DEIA599	HiB IgG ELISA Kit	96T	Human	Quantitative	serum, plasma	Inquiry
	DEIASL260	Mouse Anti-Haemophilus Influenzae B (HIB) IgG ELISA Kit	96T		Quantitative	Srerum	Inquiry
	DEIASL268	Rabbit Anti-Haemophilus Influenzae B (HIB) IgG ELISA Kit	96T		Quantitative	Srerum	Inquiry

Inquiry Basket

Loading ......

Inquiry